Nifty
Sensex
:
:
24056.00
77100.47
34.35 (0.14%)
109.25 (0.14%)

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 500087 | NSE: CIPLA

1440.10
25-Jun-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1448
  •  1453
  •  1431
  •  1437.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1217683
  •  1758041305.9
  •  1673
  •  1165.7

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,16,353.96
  • 29.99
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,15,304.51
  • 0.90%
  • 3.39

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 29.21%
  • 0.52%
  • 13.98%
  • FII
  • DII
  • Others
  • 22.55%
  • 30.17%
  • 3.57%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.94
  • 5.29
  • 3.00

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.04
  • 5.45
  • -1.33

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.39
  • 8.97
  • -1.94

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 29.47
  • 29.02
  • 27.54

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.64
  • 3.91
  • 3.99

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.46
  • 15.97
  • 15.79

Earnings Forecasts:

(Updated: 23-06-2026)
Description
2026
2027
2028
2029
Adj EPS
52.25
52.29
64.23
71.17
P/E Ratio
27.56
27.54
22.42
20.23
Revenue
28380.5
30991.8
34566.6
37946.4
EBITDA
5989.88
6098.86
7398.7
8230.58
Net Income
4227.31
4179.08
5152.11
5746.91
ROA
10.56
9.43
10.46
10.9
P/B Ratio
3.39
3.09
2.79
2.53
ROE
12.87
11.56
12.85
13.03
FCFF
3000.69
2593.27
3268.22
6372
FCFF Yield
2.98
2.57
3.24
6.32
Net Debt
-10165.5
-9777.42
-11895.6
-14772.2
BVPS
424.98
466.54
516.21
568.29

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
6,541.20
6,729.69
-2.80%
7,074.48
7,072.97
0.02%
7,589.44
7,051.02
7.64%
6,957.47
6,693.94
3.94%
Expenses
5,544.23
5,192.10
6.78%
5,819.42
5,084.05
14.46%
5,694.69
5,165.43
10.25%
5,179.33
4,978.14
4.04%
EBITDA
996.97
1,537.59
-35.16%
1,255.06
1,988.92
-36.90%
1,894.75
1,885.59
0.49%
1,778.14
1,715.80
3.63%
EBIDTM
15.24%
22.85%
17.74%
28.12%
24.97%
26.74%
25.56%
25.63%
Other Income
148.16
289.46
-48.82%
206.34
221.61
-6.89%
268.95
190.61
41.10%
258.56
160.19
61.41%
Interest
13.13
14.02
-6.35%
14.03
14.64
-4.17%
13.18
15.40
-14.42%
14.05
17.95
-21.73%
Depreciation
424.94
308.73
37.64%
278.35
279.80
-0.52%
296.99
271.74
9.29%
252.72
246.68
2.45%
PBT
707.06
1,504.30
-53.00%
893.11
1,916.09
-53.39%
1,853.53
1,789.06
3.60%
1,769.93
1,611.36
9.84%
Tax
156.95
279.28
-43.80%
218.55
332.37
-34.24%
500.46
483.04
3.61%
477.88
435.07
9.84%
PAT
550.11
1,225.02
-55.09%
674.56
1,583.72
-57.41%
1,353.07
1,306.02
3.60%
1,292.05
1,176.29
9.84%
PATM
8.41%
18.20%
9.54%
22.39%
17.83%
18.52%
18.57%
17.57%
EPS
6.87
15.13
-54.59%
8.37
19.45
-56.97%
16.73
16.13
3.72%
16.06
14.58
10.15%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
-
28,162.59
27,547.62
25,774.09
22,753.12
21,763.34
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
Net Sales Growth
-
2.23%
6.88%
13.28%
4.55%
13.59%
11.84%
4.70%
7.96%
5.29%
 
Cost Of Goods Sold
-
9,549.11
8,928.99
8,819.57
8,252.28
8,495.60
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
Gross Profit
-
18,613.48
18,618.63
16,954.52
14,500.84
13,267.74
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
GP Margin
-
66.09%
67.59%
65.78%
63.73%
60.96%
61.63%
65.03%
64.65%
64.12%
63.06%
Total Expenditure
-
22,279.69
20,424.78
19,483.04
17,762.83
17,251.38
14,910.94
13,951.18
13,265.10
12,329.33
11,918.50
Power & Fuel Cost
-
416.79
397.18
364.84
353.61
331.03
308.26
327.43
335.11
298.82
251.73
% Of Sales
-
1.48%
1.44%
1.42%
1.55%
1.52%
1.61%
1.91%
2.05%
1.97%
1.75%
Employee Cost
-
5,366.33
4,832.83
4,310.04
3,830.08
3,529.91
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
% Of Sales
-
19.05%
17.54%
16.72%
16.83%
16.22%
16.97%
17.67%
17.46%
17.75%
18.30%
Manufacturing Exp.
-
2,174.08
1,894.12
1,779.35
1,589.90
1,453.22
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
% Of Sales
-
7.72%
6.88%
6.90%
6.99%
6.68%
6.30%
8.01%
7.85%
8.05%
8.29%
General & Admin Exp.
-
1,868.24
1,772.59
1,673.94
1,423.23
1,206.07
986.01
1,289.13
1,096.50
1,002.43
868.31
% Of Sales
-
6.63%
6.43%
6.49%
6.26%
5.54%
5.15%
7.52%
6.70%
6.61%
6.03%
Selling & Distn. Exp.
-
1,934.24
1,834.86
1,724.97
1,694.30
1,670.00
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
% Of Sales
-
6.87%
6.66%
6.69%
7.45%
7.67%
6.78%
7.31%
7.83%
7.15%
7.01%
Miscellaneous Exp.
-
970.90
764.21
810.33
619.43
565.55
508.00
692.12
626.24
595.99
1,009.21
% Of Sales
-
3.45%
2.77%
3.14%
2.72%
2.60%
2.65%
4.04%
3.83%
3.93%
4.48%
EBITDA
-
5,882.90
7,122.84
6,291.05
4,990.29
4,511.96
4,248.65
3,180.81
3,097.31
2,826.38
2,475.79
EBITDA Margin
-
20.89%
25.86%
24.41%
21.93%
20.73%
22.18%
18.57%
18.93%
18.65%
17.20%
Other Income
-
882.01
866.93
746.57
512.13
321.73
269.77
369.38
476.57
357.65
228.69
Interest
-
54.39
62.01
89.88
109.54
106.35
160.70
197.36
168.43
114.23
159.38
Depreciation
-
1,210.98
1,106.95
1,051.02
1,172.11
1,051.95
1,067.66
1,174.65
1,326.31
1,322.82
1,322.93
PBT
-
5,499.54
6,820.81
5,896.72
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
Tax
-
1,353.84
1,529.76
1,546.59
1,202.86
933.80
888.76
631.20
569.53
250.11
179.76
Tax Rate
-
25.92%
22.43%
27.12%
29.79%
26.73%
27.01%
28.98%
27.39%
14.98%
14.71%
PAT
-
3,887.28
5,294.37
4,123.14
2,804.51
2,529.57
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
PAT before Minority Interest
-
3,869.79
5,291.05
4,155.31
2,835.49
2,559.47
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
Minority Interest
-
17.49
3.32
-32.17
-30.98
-29.90
16.36
47.00
35.26
-6.04
-29.03
PAT Margin
-
13.80%
19.22%
16.00%
12.33%
11.62%
12.62%
9.30%
9.44%
9.33%
7.04%
PAT Growth
-
-26.58%
28.41%
47.02%
10.87%
4.63%
51.67%
3.18%
9.31%
39.46%
 
EPS
-
48.27
65.74
51.19
34.82
31.41
30.02
19.79
19.18
17.55
12.58

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
34,431.95
31,193.45
26,706.43
23,407.78
20,841.69
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
Share Capital
161.56
161.52
161.47
161.43
161.36
161.29
161.25
161.14
161.02
160.90
Total Reserves
34,207.89
30,917.81
26,458.42
23,184.53
20,636.35
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
Non-Current Liabilities
61.13
-31.04
81.92
183.53
621.70
1,660.06
2,972.37
4,646.15
4,259.05
4,513.35
Secured Loans
0.00
0.00
0.00
332.46
376.20
355.32
304.74
47.70
0.00
0.00
Unsecured Loans
117.47
11.98
0.00
-332.46
40.04
847.43
2,064.54
3,782.37
3,662.11
3,645.36
Long Term Provisions
157.56
148.69
129.26
102.16
100.22
116.17
133.27
121.41
137.92
140.52
Current Liabilities
7,013.59
5,483.96
5,245.77
5,033.27
4,912.87
4,591.14
4,393.14
3,771.51
3,832.22
3,373.70
Trade Payables
3,229.90
2,837.49
2,473.98
2,534.52
2,508.10
2,066.82
2,281.81
1,947.99
2,119.12
1,571.14
Other Current Liabilities
1,378.59
772.99
890.98
1,007.60
769.81
1,093.21
706.65
541.86
647.04
908.95
Short Term Borrowings
140.50
80.12
247.02
187.90
393.34
334.73
447.15
486.16
435.87
467.23
Short Term Provisions
2,264.60
1,793.36
1,633.79
1,303.25
1,241.62
1,096.38
957.53
795.50
630.19
426.38
Total Liabilities
41,594.96
36,742.17
32,130.02
28,930.34
26,651.95
24,836.79
23,422.79
23,761.91
22,672.90
20,868.94
Net Block
12,434.36
9,895.14
9,493.61
9,100.65
9,621.91
9,393.77
9,558.59
9,546.51
9,949.14
9,490.24
Gross Block
23,825.03
19,655.92
18,160.54
17,204.76
16,968.35
15,647.05
14,913.62
13,790.31
12,960.01
11,352.78
Accumulated Depreciation
11,343.39
9,707.76
8,573.36
7,994.72
7,310.84
6,216.82
5,309.30
4,233.78
3,010.87
1,609.71
Non Current Assets
17,447.93
13,453.65
12,688.61
11,731.79
11,924.75
11,627.69
11,716.61
11,335.28
11,858.80
12,064.31
Capital Work in Progress
2,042.22
1,566.27
1,152.72
1,093.30
766.18
968.89
824.53
676.18
981.33
1,682.98
Non Current Investment
543.99
639.54
642.21
572.52
355.63
423.68
454.50
428.35
156.63
135.62
Long Term Loans & Adv.
1,321.80
1,038.36
844.39
849.46
736.39
645.57
677.08
455.57
514.96
543.67
Other Non Current Assets
1,105.56
203.09
442.07
56.03
383.22
74.03
77.61
166.82
255.71
210.06
Current Assets
24,145.86
23,248.97
19,392.45
16,805.06
14,710.83
13,181.03
11,703.84
12,424.63
10,814.10
8,735.57
Current Investments
7,679.42
7,293.23
4,807.01
3,089.86
2,194.97
2,286.37
1,016.52
2,125.79
1,102.21
837.39
Inventories
6,596.72
5,642.11
5,237.95
5,156.43
5,350.24
4,669.18
4,377.60
3,964.83
4,044.70
3,485.28
Sundry Debtors
5,620.05
5,506.37
4,770.66
4,057.00
3,424.44
3,445.68
3,891.31
4,150.72
3,102.45
2,563.05
Cash & Bank
1,307.42
799.84
874.97
1,564.62
1,928.48
1,401.23
1,003.91
618.81
965.61
624.21
Other Current Assets
2,942.25
526.00
567.64
373.99
1,812.70
1,378.57
1,414.50
1,564.48
1,599.13
1,225.64
Short Term Loans & Adv.
2,367.55
3,481.42
3,134.22
2,563.16
1,507.14
1,031.03
974.82
1,150.95
1,118.93
807.47
Net Current Assets
17,132.27
17,765.01
14,146.68
11,771.79
9,797.96
8,589.89
7,310.70
8,653.12
6,981.88
5,361.87
Total Assets
41,593.79
36,702.62
32,081.06
28,536.85
26,635.58
24,808.72
23,420.45
23,759.91
22,672.90
20,799.88

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
3,940.02
5,004.98
4,133.91
3,237.65
3,325.90
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
PBT
5,223.63
6,820.81
5,896.72
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
Adjustment
527.81
517.74
640.77
878.19
967.47
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
Changes in Working Capital
-225.22
-665.47
-806.10
-559.42
-177.46
371.66
372.99
-1,063.54
-778.48
235.44
Cash after chg. in Working capital
5,526.22
6,673.08
5,731.39
4,539.54
4,465.40
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,586.20
-1,668.10
-1,597.48
-1,301.89
-1,139.50
-1,037.43
-848.25
-593.23
-722.04
-450.27
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,326.13
-3,691.14
-2,988.03
-2,388.51
-1,871.88
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
Net Fixed Assets
-2,339.05
-626.50
-373.49
-600.42
-321.93
-437.48
-450.41
-173.16
-509.84
-889.04
Net Investments
-265.34
-3,557.23
-1,884.41
-935.67
-1,247.85
-2,536.08
-1,374.56
-1,178.21
-351.09
-30.11
Others
278.26
492.59
-730.13
-852.42
-302.10
586.38
1,929.01
-317.31
6.92
-391.06
Cash from Financing Activity
-1,233.65
-1,292.79
-1,200.43
-958.29
-1,599.79
-1,239.51
-2,948.82
-348.72
-385.48
-1,325.68
Net Cash Inflow / Outflow
380.24
21.05
-54.55
-109.15
-145.77
128.51
223.67
-326.26
223.27
-254.13
Opening Cash & Equivalents
542.65
512.34
561.33
658.11
790.43
649.13
508.36
853.47
610.35
858.15
Closing Cash & Equivalent
1,015.39
542.65
512.34
561.33
658.11
790.43
742.38
508.36
853.46
610.35

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
425.47
384.84
329.72
289.24
257.78
226.73
194.85
185.62
175.92
155.15
ROA
9.88%
15.36%
13.59%
10.19%
9.94%
9.95%
6.56%
6.50%
6.52%
4.97%
ROE
11.83%
18.34%
16.63%
12.85%
13.10%
14.13%
10.09%
10.37%
10.65%
8.72%
ROCE
16.00%
23.64%
22.77%
18.19%
17.24%
17.85%
12.53%
11.94%
10.20%
8.28%
Fixed Asset Turnover
1.79
1.96
2.00
1.81
1.82
1.85
1.89
1.79
1.25
1.36
Receivable days
52.05
50.64
45.49
44.13
42.19
47.44
54.10
55.36
68.17
61.60
Inventory Days
57.25
53.61
53.56
61.98
61.53
58.49
56.12
61.13
90.71
91.41
Payable days
115.96
108.56
103.64
111.52
98.28
107.95
128.84
59.02
57.37
46.96
Cash Conversion Cycle
-6.65
-4.31
-4.58
-5.41
5.44
-2.02
-18.63
57.47
101.50
106.05
Total Debt/Equity
0.01
0.00
0.01
0.02
0.04
0.10
0.18
0.29
0.29
0.33
Interest Cover
97.04
111.00
64.44
37.87
33.85
21.47
12.04
13.34
15.61
8.67

News Update:


  • Cipla - Quarterly Results
    14th May 2026, 00:00 AM

    Read More
  • Cipla’s consolidated net profit falls 55% in Q4
    13th May 2026, 15:30 PM

    The total consolidated income of the company decreased by 4.70% at Rs 6,689.36 crore for Q4FY26

    Read More
  • Cipla’s arm gets USFDA’s final nod for Albuterol Sulfate Inhalation Aerosol
    23rd Apr 2026, 10:57 AM

    This approval enhances Cipla’s U.S. respiratory portfolio and reinforces its leadership in the Albuterol inhalation category

    Read More
  • USFDA concludes inspection at Cipla’s Goa manufacturing facility
    18th Apr 2026, 12:36 PM

    On conclusion of the inspection, the Company received two inspectional observations in Form 483

    Read More
  • Cipla gets nod to invest upto $100 million in Cipla (EU)
    20th Mar 2026, 11:38 AM

    The board at its meeting held on March 19, 2026 has approved the same

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.